The current status of adenovirus-based cancer gene therapy

Molecules and Cells

Volumn 25, Issue 4, 2008, Pages 462-466

  Shirakawa, Toshiro ^a,b  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adenovirus; Cancer; Gene therapy

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; ESTRAMUSTINE; GENDICINE; ONCOLYTIC ADENOVIRUS; ONCOLYTIC HERPES VIRUS; PROTEIN P53; TRANSMEMBRANE CONDUCTANCE REGULATOR; VIRUS DNA;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; CANCER GENE THERAPY; CANCER INHIBITION; CELL BASED GENE THERAPY; CLINICAL TRIAL; CYSTIC FIBROSIS; DRUG DELIVERY SYSTEM; DRUG MECHANISM; HEAD AND NECK CARCINOMA; HUMAN; IN VIVO GENE TRANSFER; LUNG NON SMALL CELL CANCER; NONHUMAN; ONCOLYTIC VIROTHERAPY; PROSTATE CANCER; SHORT SURVEY; UTERINE CERVIX CANCER; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS GENOME; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY;

ADENOVIRIDAE; MIRIDAE;

EID: 57349167467     PISSN: 10168478     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (29)

1. Biederer, C., Ries, S., Brandts, C.H., and Mccormick, F. (2002). Replication-selective viruses for cancer therapy. J. Mol. Med. 80, 163-175.
2. Clayman, G.L., El-naggar, A.K., Lippman, S.M., Henderson, Y.C., Frederick, M., Merritt, J.A., Zumstein, L.A., Timmons, T.M., Liu, T.J., Ginsberg, L., et al. (1998). Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J. Clin. Oncol. 16, 2221-2232.
3. Crystal, R.G., Mcelvaney, N.G., Rosenfeld, M.A., Chu, C.S., Mastrngeli, A., Hay, J.G., Brody, S.L., Jaffe, H.A., Eissa, N.T., and Danel, C. (1994). Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat. Genet. 8, 42-51.
4. Fallaux, F.J., Bout, A., Van der Velde, I., Van den Wollenberg, D.J., Hehir, K.M., Keegan, J., Auger, C., Cramer, S.J., Van Ormondt, H., Van der EB, A.J., et al. (1998). New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-com-petent adenoviruses. Hum. Gene Ther. 9, 1909-1917.
5. Freytag, S.O., Stricker, H., Pegg, J., Paielli, D., Pradhan, D.G., Peabody, J., Deperalta-Venturian, M., Xia, X., Brown, S., Lu, M., et al. (2003). Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate-to high-risk prostate cancer. Cancer Res. 63, 7497-7506.
6. Ganly, I., Kirn, D., Eckhardt, G., Rodriguez, G.I., Soutar, D.S., Otto, R., Robertson, A.G., Park, O., Gulley, M.L., Heise, C., et al. (2000). A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin. Cancer Res. 6, 798-806.
7. Graham, F.L., Smiley, J., Russell, W.C., and Nairn, R. (1977). Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59-74.
8. Hamada, K., Desaki, J., Nakagawa, K., Zhang, T., Shirakawa, T., Gotoh, A., and Tagawa, M. (2007). Carrier cell-mediated delivery of a replication-competent adenovirus for cancer gene therapy. Mol. Ther. 15, 1121-1128.
9. Huebner, R.J., Rowe, W.P., Schatten, W.E., Smith, R.R., and Thomas, L.B. (1956). Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 9, 1211-1218.
10. Kreppel, F., and Kochanek, S. (2008). Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. Mol. Ther. 16, 16-29.
11. Lonberg-Holm, K., and Philipson, L. (1969). Early events of virus-cell interaction in an adenovirus system. J. Virol. 4, 323-338.
12. Mettler, N.E., Clarke, D.H., and Casals, J. (1982). Virus inoculation in mice bearing Ehrlich ascitic tumors: antigen production and tumor regression. Infect. Immun. 37, 23-27.
13. Mizuguchi, H., and Hayakawa, T. (2004). Targeted adenovirus vectors. Hum. Gene Ther. 15, 1034-1044.
14. Nemunaitis, J., Swisher, S.G., Timmons, T., Connors, D., Mack, M., Doerksen, L., Weill, D., Wait, J., Lawrence, D.D., Kemp, B.L., et al. (2000). Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J. Clin. Oncol. 18, 609-622.
15. Peng, Z. (2005). Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum. Gene Ther. 16, 1016-1027.
16. Power, A.T., and Bell, J.C. (2007). Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer. Mol. Ther. 15, 660-665.
17. Raper, S.E., Chirmule, N., Lee, F.S., Wivel, N.A., Bagg, A., Gao, G.P., Wilson, J.M., and Batshaw, M.L. (2003). Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. 80, 148-158.
18. Rowe, W.P., Huebner, R.J., Gilmore, L.K., Parrott, R.H., and Ward, T.G. (1953). Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc. Soc. Exp. Biol. Med. 84, 570-573.
19. Russell, W.C. (2000). Update on adenovirus and its vectors. J. Gen. Virol. 81, 2573-2604.
20. Sakhuja, K., Reddy, P.S., Ganesh, S., Cantaniag, F., Pattison, S., Limbach, P., Kayda, D.B., Kadan, M.J., Kaleko, M., and Connelly, S. (2003). Optimization of the generation and propagation of gutless adenoviral vectors. Hum. Gene Ther. 14, 243-254.
21. Saukkonen, K., and Hemminki, A. (2004). Tissue-specific promoters for cancer gene therapy. Expert Opin. Biol. Ther. 4, 683-696.
22. Shirakawa, T., Terao, S., Hinata, N., Tanaka, K., Takenaka, A., Hara, I., Sugimura, K., Matsuo, M., Hamada, K., Fuji, K., et al. (2007). Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer. Hum. Gene Ther. 18, 1225-1232.
23. Southam, C.M., and Moore, A.E. (1952). Clinical studies of viruses as antineoplastic agents with particular reference to Egypt 101 virus. Cancer 5, 1025-1034.
24. Southam, C.M., Hilleman, M.R., and Werner, J.H. (1956). Pathogenicity and oncolytic capacity of RI virus strain RI-67 in man. J. Lab Clin. Med. 47, 573-582.
25. Vaha-Koskela, M.J., Heikkila, J.E., and Hinkkanen, A.E. (2007). Oncolytic viruses in cancer therapy. Cancer Lett. 254, 178-216.
26. Vattemi, E., and Claudio, P.P. (2006). Adenoviral gene therapy in head and neck cancer. Drug News Perspect. 19, 329-337.
27. Volpers, C., and Kochanek, S. (2004). Adenoviral vectors for gene transfer and therapy. J. Gene Med. 6 (Suppl. 1), S164-171.
28. Yu, W., and Fang, H. (2007). Clinical trials with oncolytic adenovirus in China. Curr. Cancer Drug Targets 7, 141-148.
29. Zeimet, A.G., and Marth, C. (2003). Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol. 4, 415-422.